Let’s say that you are a CEO of a big pharmaceutical concern, and you have one of the very few vaccinations available for the Trump-Virus and you pretty much a lock on a captive, world-wide market?
Pfizer is looking to turn its lucrative coronavirus vaccine into an even bigger cash cow. The drugmaker sees a “significant opportunity” to charge more for the groundbreaking shot once it gets to the other side of the COVID-19 pandemic, one top executive says…. For instance, Pfizer is charging the U.S. government $19.50 per dose—well below the $150 or $175 per dose it typically pulls in for a vaccine, [chief financial officer Frank] D’Amelio said on the company’s February earnings call. But “normal market conditions will start to kick in” as the global pandemic shifts into an endemic, D’Amelio said last week…. Those profits could get even larger once Pfizer gets out of the “pandemic-pricing environment,” D’Amelio told investors last month.
Pfizer is expected to rake in $15B Ameros in sales from its two-dose vaccine this year. But, you know, once you have the patient over the barrel…
“Obviously, we’re going to get more on price,” D’Amelio said. “And clearly…the more volume we put through our factories, the lower unit cost will become.”
Pure profit from all the annual booster shots we will need as the variants come in waves.